

Role of Triiodothyronine in Hypothyroidism: Consensus statement from Indian Thyroid Society



Role of Triiodothyronine in Hypothyroidism: Consensus statement from Indian Thyroid Society

Authors

Dr Shashank R Joshi¹, Dr Krishna Sheshadri², Dr Pramila Kalra³, Dr Sujoy Ghosh⁴, Dr Arun S Menon⁵, Dr Mini G. Pillai⁶, Dr Himagirish Rao⁷, Dr Mohan Shenoy⁸, Dr Joe George⁹, Dr Roma Pradhan¹⁰, Dr Saptarshi Bhattacharya¹¹, Dr Kumaravel V¹²

Affiliations:

1. Consultant Endocrinologist. Department of Endocrinology, Joshi Clinic and Lilavati Hospital and Research Centre, Mumbai, India
2. Consultant Endocrinologist, Chennai Diabetes and Endocrine Clinic, Chennai, Tamil Nadu
3. Department of Endocrinology, M. S. Ramaiah Medical College, Bangalore, Karnataka, India
4. Department of Endocrinology and Metabolism, Institute of Post-Graduate Medical Education and Research, Kolkata, West Bengal
5. Department of Endocrinology, Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala, India Endocrinology, Lakshmi Hospital, Ernakulam, Kerala
6. Consultant Endocrinologist, Lakshmi Hospital, Ernakulam, Kochi, Kochi
7. Clinic of General Surgery, St. Johns Medical College Hospital, Bengaluru, India
8. Department of Endocrinology, Sree Gokulam Medical college, Venjarumoodu, Trivandrum
9. Endocrinology, Endodiab Clinic, Kozhikode, Kerala
10. Endocrine Surgery, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow
11. Department of Endocrinology, Indraprastha Apollo Hospitals, Delhi
12. Endocrinology and Diabetes, Alpha hospital & Research center, Madurai, Tamil Nadu

Introduction

Hypothyroidism is a chronic condition associated with the deficiency of thyroid hormone (thyroxine (T4) and triiodothyronine (T3)).¹ Globally, the prevalence of hypothyroidism is increasing gradually.² Up to 5% of the general population is affected by hypothyroidism, with an additional estimated 5% remaining undiagnosed.¹ The prevalence of hypothyroidism in India is over twice as high as in Western countries.³ The data from a cross-sectional study conducted in India revealed that the overall prevalence of hypothyroidism was 10.95% with 8.02% of patients diagnosed with subclinical hypothyroidism.⁴

The symptoms of hypothyroidism are generally non-specific and diverse. They include mild to moderate weight gain, fatigue, poor concentration, depression, and menstrual irregularities. If left untreated, hypothyroidism can lead to serious consequences such as cardiovascular disease and increased mortality.¹

The goal of treatment is to relieve symptoms and normalize thyroid hormone levels, with Levothyroxine (LT4) being the primary medication used to manage hypothyroidism.^{1,5} Despite appropriate diagnosis and treatment, nearly one-third of patients with hypothyroidism continue to experience symptoms reminiscent of hypothyroidism, impairing their quality of life. Therefore, optimizing LT4 therapy and identifying those who may benefit from a combination of LT4 and liothyronine (LT3) therapy is crucial.¹ In addition to the growing interest in using combination therapy with LT4/LT3 for hypothyroid patients, LT3 is also employed in the preparation of postoperative thyroid cancer patients before radioactive iodine ablation.⁵

Objective

The aim of this consensus is to update recommendations for the appropriate management of a subset of hypothyroid individuals who experience suboptimal outcomes on LT4 monotherapy.

Methods

The sections and recommendations addressed in the consensus were formulated based on insights from previous trials and guidelines. This document provides much-required insights and useful, practical, and accurate guidance that aids a practicing clinician. The draft was prepared meticulously by the members of the Indian Thyroid Society with a series of reviews and modifications.

A well-defined grading system (Table 1) for the critical appraisal of evidence and grading strength of recommendations was followed.

Table 1. Level of evidence and grading strength of recommendations

Level of evidence	Description
Level A	Data derived from multiple randomized trials or meta-analyses or evidence-based clinical practice guidelines
Level B	Data derived from a single randomized trials or large non-randomized trial
Level C	The consensus of opinion of experts or small studies, retrospective studies or registries or narrative/literature reviews
Level D	Data derived from Clinical experience
Class of recommendations	
Class I	Evidence and or general agreement that a given treatment or procedure is beneficial, useful or effective. It is recommended
Class IIa	Evidence is in favor of efficacy/usefulness and should be considered
Class IIb	Efficacy/usefulness is less well established and recommendations may be considered

Class III	Evidence and or general agreement that a given treatment or procedure is not beneficial, useful or effective and in some cases may cause harm. Not recommended.
-----------	---

1. Clinical question: What is the role of LT3 in the management of hypothyroidism in the below mentioned clinical scenarios?

A. Refractory Hypothyroidism

Primary hypothyroidism is considered treatment refractory when clinical or biochemical signs of hypothyroidism (level of TSH above the target range, usually 5.5 mIU/L) persist despite increasing dosages of LT4 > 1.9µg/kg /day.^{6,7} Approximately 15–20% of patients taking L-T4 experience refractory hypothyroidism.^{8,9}

In such situation, further increasing the thyroxine dose may not always resolve the issue. Additionally, supratherapeutic doses can lead to cardiovascular and other side effects. If unexpectedly high doses of thyroxine are required, then the first step in the evaluation is to check the compliance of the patient. If the patient adheres to the prescribed treatment, a levothyroxine absorption test to differentiate between true malabsorption and pseudo malabsorption can be included here. However, the dilemma remains as to whether adding T3 would help in cases of true malabsorption. Other potential causes of refractory hypothyroidism such as switching to a generic levothyroxine with different bioavailability, drugs that treat gastrointestinal conditions/dietary considerations, pregnancy, concomitant gastrointestinal diseases, and changes in body weight/body mass should be investigated.¹⁰

Poor conversion of T4 to T3 is one of the causes of refractory hypothyroidism. It has been suggested that a genetic variation in deiodinase D2 may help to explain why some patients who do not achieve control of their hypothyroidism with LT4 therapy respond better to the LT4/LT3 combination therapy.^{6,10} This alteration was observed in 16% of the "poor converters" studied.¹⁰

In a subset of individuals, insufficient deiodination of T4 to T3 leads to an inability to attain physiological T3 levels in the tissues, manifesting as tissue hypothyroidism. Hence, in about 15% of hypothyroid individuals treated with levothyroxine, the normalization of serum TSH levels is associated with higher T4 concentrations and below-normal serum T3 concentrations, resulting in a decreased serum T3/T4 ratio.¹¹

In 2012, European Thyroid Association (ETA) released a guideline on the use of LT4/LT3 in the treatment of hypothyroidism which revealed the data on the preference of patients for either T4 monotherapy vs. LT4/LT3 combination therapy in a randomized control, cross-over, or parallel study designs. The results indicated that 27% of participants preferred LT4 monotherapy, 25% had no preference, and 48% favoured the LT4/LT3 combination therapy (Table 2). Patient preference for combination therapy was linked to improvements in quality of life, cognition, mood, and symptoms.¹¹

A systematic review and meta-analysis of seven blinded randomized controlled trials involving 348 individuals with hypothyroidism showed that approximately half of participants reported preferring combination L-T3 and L-T4 therapy compared to L-T4 alone.¹² Another systematic review and meta-analysis found no significant advantage in improving psychological health with T4 + T3 combination therapy compared to T4 monotherapy.¹³

The recommendation by ETA 2012 states that LT4/LT3 combination therapy might be considered as an experimental approach in compliant LT4-treated hypothyroid patients who have persistent complaints despite serum TSH values within the reference range, provided they have previously been given support to deal with the chronic nature of their disease and associated autoimmune diseases have been ruled out. It also provides guidance on long-term therapy by adding that a period of 3

months for the trial seems reasonable in view of the finding that any improvement upon LT4/LT3 combination treatment initiation in the randomized clinical trials was observed in this time frame. If LT4/LT3 combination therapy is effective and well tolerated, it may be continued beyond the trial period.¹¹

Table 2: Preference of patients in RCTs comparing T4 monotherapy with LT4/LT3 combination therapy in cross-over or parallel study designs¹¹

Author	N	Preference T4 monotherapy	No particular preference	Preference T4 + T3 therapy	p value
Walsh et al.	100	46	18	36	0.32
Nygaard et al.	59	9	21	29	0.002
Bunevicius et al.	33	2	11	20	0.001
Escobar-Morreale et al.	26	2	6	18	0.015
Bunevicius et al.	10	2	2	6	-
Total	228	61 (27%)	58 (25%)	109 (48%)	

Various guidelines have also reached a consensus on the use of LT3 therapy in refractory hypothyroidism

Guideline	Recommendation/Consensus statement
2023 Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for Endocrinology consensus statement ¹⁴	For patients with confirmed overt hypothyroidism and experiencing ongoing symptoms despite sufficient LT4 treatment, and where other potential comorbidities have been ruled out, a trial of combined LT3 and LT4 therapy might be considered.
2014 Guidelines for the Treatment of Hypothyroidism Prepared by the American Thyroid Association ¹⁵	There is currently insufficient evidence to support the routine use of a trial of a combination of LT4 and LT3 therapy.
2013 Clinical practice guidelines for the management of hypothyroidism: Thyroid consensus – Brazil ¹⁶	If symptoms of hypothyroidism continue despite proper treatment, it is important to rule out other potential comorbidities. Increasing the LT4 dosage or using a combination therapy with triiodothyronine is not advised.
2012 ETA Guidelines: The Use of LT4/LT3 in the Treatment of Hypothyroidism ¹¹	The LT4/LT3 combination therapy should be regarded as an experimental treatment option.

Consensus statement

- There is a limited evidence from randomized controlled trials and long-term studies demonstrating that the combination therapy is superior to LT4 alone, however majority of the patients have preferred the LT4/LT3 combination therapy. Hence, a trial of combined LT3 and LT4 therapy may be considered in patients on long-term levothyroxine therapy with ongoing symptoms and where other comorbidities have been ruled out. (A/IIb)

B. Preoperative management of hypothyroidism

Patients with hypothyroidism may occasionally need surgery.¹⁷ Low levels of serum thyroid may affect clinical outcomes in the perioperative period.¹⁸ However, limited data is available on the use of oral T3 in this context. For patients with severe hypothyroidism requiring urgent or emergency surgery, perioperative treatment with IV T3 or T4, alone or in myxedema coma, the combination with glucocorticoids is generally administered. Elective surgeries should be postponed until these patients achieve euthyroid status, which typically requires six weeks to two months of oral thyroxine therapy.¹⁷

In a case-based study conducted in India, 12 patients with hypothyroidism and severe neurological symptoms who were planned for semi-urgent neurosurgical procedures within a week of presentation were administered 100 µg T4. Moreover, the patients were managed perioperatively by administering oral T3 in addition to oral T4. Oral T3 was given at a dosage of 20 µg, three times daily, for five days before the surgery and continued at the same dosage for three days following the surgery. After administering the medication, the authors did not observe any perioperative complications related to low thyroid hormone levels. Additionally, all patients remained hemodynamically stable during the perioperative period and the authors did not observe any adverse effects of cardiovascular stimulation or angina. The study demonstrated that patients with hypothyroidism can be considered for semi-urgent surgeries with adequate perioperative oral T3 supplementation along with oral T4 without any perioperative complications.¹⁷

A Class I Level D recommendation by a 2007 guideline for perioperative evaluation revealed that:¹⁹

- Elective surgery should only take place when the thyroid function of the patient is normal.
- The half-lives of T4 and T3 are 7 days and 1.5 days, respectively. Therefore, a patient on T4 can skip their dose on the day of elective surgery, while a patient on T3 should take their medication as scheduled.
- For patients with severe hypothyroidism or myxedema coma undergoing urgent surgeries
 - Administer 40 µg of IV T3 or 10-25 µg of oral T3 at 8 hour intervals before surgery.
 - For maintenance, administer IV LT3 at a dose of 10–20 µg every 24 hours.

Palace et al., conducted research on perioperative management of thyroid dysfunction in 2017 which concluded with the following recommendation:²⁰

- Non-emergent surgery should be postponed until the hypothyroidism has been treated.
- For patients suspected of having myxedema coma who need urgent surgery, it is crucial to quickly normalize thyroid hormone levels by concurrently administering LT3 and IV LT4 (loading dose of 200 to 500 µg followed by 50 to 100 µg IV daily).

A 2022 literature review conducted by Manzullo and Malhotra et al., revealed that IV LT3 should be administered concurrently with LT4 therapy at a dose of 5 to 20 µg. Subsequently, LT3 at a dose of 2.5 to 10 µg should be given every eight hours, adjusted according to the patient's age and any existing cardiac risk factors.^{21,22}

Consensus statement

- No data is available regarding the optimal dose of LT4 and LT3 to be used in this situation in the perioperative period in People who require emergency surgery with sub optimally controlled hypothyroid status. If initiating thyroid replacement therapy for the first time, It may be prudent to initiate thyroid hormone therapy with low doses of LT3 (5-10 mcg every 8 hours IV or PO). If the patient is already on chronic therapy, 50% of prior dose may be continued as T4 and 50% as T3. (C/Iib)

C. Myxedema Coma

Myxedema coma is a life-threatening condition caused by prolonged hypothyroidism, where the body's ability to maintain homeostasis is severely impaired. Despite early diagnosis and treatment of myxedema coma, the mortality rate varies significantly, ranging from as high as 60% to as low as 20–25% even when advanced intensive care is available.²³ The underlying cause of myxedema coma is the reduction of intracellular T3 secondary to hypothyroidism, leading to hypothermia and decreased cardiac function.²⁴ Therefore, timely diagnosis and treatment are crucial for managing myxedema coma effectively.²⁵ The management of myxedema coma requires a multidisciplinary treatment plan, including respiratory support, circulatory stabilization, adrenocortical hormone therapy, and thyroid hormone replacement. Of these treatments, thyroid hormone replacement therapy with LT4 is particularly crucial.²⁶ Administering LT4 alone resulted in a steady and smooth, although slower, onset of action with a low risk of adverse effects. In contrast, LT3 had a quicker onset, reaching peak levels within 2 to 4 hours after administration. Its 10–20-fold higher affinity for the nuclear receptor compared to T4 may be crucial for enhancing survival rates.^{25,26}

A retrospective observational study was conducted among patients diagnosed with myxedema coma. The research focused on the mortality rate among patients receiving the LT4/LT3 combination (n=120) vs. LT4 alone (n=11). The maximal per-day dosage of LT4 was categorized into <100, 100–199, and ≥ 200 μg , and the maximal per-day dosage of LT3 was categorized into <20, 20–49, and ≥ 50 μg . The results from the research revealed that patients treated with a combination therapy experienced lower mortality rates compared to those on LT4 alone, however, this difference was statistically insignificant (18.2% vs. 30.0%, $p=0.66$). The results from the research could not provide recommendations regarding the dosage and use of LT4 alone or both LT4 and LT3 for managing myxedema coma due to the small sample size and unknown severity of the myxedema coma.²⁷

In a case series of data from 8 patients, Yamamoto et al., treated the first 3 myxedema coma patients with high-dose IV LT3 and the other 5 patients with a smaller amount of either LT3 or LT4 (LT4 ≥ 500 $\mu\text{g}/\text{d}$ or LT3 ≥ 75 $\mu\text{g}/\text{day}$). The results revealed that two of three patients treated with high-dose LT3 died, whereas the other five who were treated with smaller doses of LT3 or LT4 survived. The authors concluded that high doses of LT3 (≥ 75 $\mu\text{g}/\text{day}$) were associated with fatal outcomes.²⁸

In a case study, an 84-year-old Japanese man diagnosed with myxedema coma was promptly administered intensive supportive care and a combined treatment of 200 μg LT4 and 50 μg LT3 for the first five days of hospitalization. This was then switched to LT4 monotherapy at a daily dose of 150 μg . The treatment approach successfully normalized thyroid hormone levels within a few days without leading to any cardiovascular disease. The case highlighted the effectiveness of combining LT4/LT3 in treating myxedema coma.²⁵

In another case study, a patient experienced presyncope alongside generalized fatigue, reduced appetite, lack of interest in usual activities, and slowed speech and movement. A comprehensive examination identified pituitary dysfunction, leading to diagnosis of myxedema coma and adrenal crisis. The patient was treated with a regimen of 300 μg IV LT4 and 5 mcg IV LT3 every 8 hours, resulting in complete symptom resolution. There were no observed endocrinological complications, and then the patient was advised to continue with oral only LT4. This combined treatment approach effectively managed the myxedema coma.²⁹

Guidelines for the treatment of hypothyroidism prepared by the American Thyroid Association Task Force on thyroid hormone replacement revealed a weak recommendation with low-quality evidence that IV LT3 may be administered in addition to LT4. High doses should be avoided due to the link between elevated serum T3 levels during treatment and increased mortality. The treatment should include a loading dose of 5–20 μg , followed by a maintenance dose of 2.5–10 μg every 8 hours. A low dosing range can be chosen for patients who are elderly, as well as those with a history of coronary artery disease or arrhythmias. Therapy should be maintained until the patient shows signs of

recovery or demonstrates improvement in clinical parameters.¹⁵ In another 2013 clinical practice guidelines for the management of hypothyroidism, it was suggested that the addition of 10-20 mg bolus of T3 to the T4 therapy followed by 10 µg of T3 every 4-6 hours.¹⁶

Consensus statement

- Administration of LT3 in addition to LT4 therapy in patients diagnosed with myxedema coma resulted in normalization of thyroid hormone levels and resolution of symptoms, leading to successful management of the disease. (D/IIa)
- Administration of LT3 therapy in patients diagnosed with myxedema coma was associated with lower mortality rates. However, a dose of ≥ 75 µg/day was associated with fatal outcomes. (D/IIa)

D. LT3 in thyroid hormone withdrawal as preparation for radioactive iodine ablation

Radioactive iodine ablation (RAI) is administered following a total thyroidectomy to eliminate any normal thyroid remnant and microscopic residual disease.³⁰ The administration of RAI required TSH stimulation, which could be accomplished through one of two methods: (i) withdrawing LT4 and LT3 to induce endogenous TSH elevation (thyroid hormone withdrawal [THW]) or (ii) using recombinant human TSH (rhTSH) for exogenous stimulation.³¹ However, the effectiveness is unclear.

A retrospective study compared the effectiveness and side effects of THW vs. rhTSH preparation for RAI therapy in metastatic differentiated thyroid carcinoma (DTC). The study included 56 patients with RAI-avid distant metastases of DTC. These patients were treated with either rhTSH (n=15) or THW (n=41) and were monitored for a period ranging from 72 months. In the THW group, LT4 was discontinued approximately 6 weeks before treatment. After total thyroidectomy, patients in this group were given LT3 for 4 weeks and then withdrawn from it 2 weeks prior to RAI therapy. The results of the research revealed that complete response, stable disease, progressive disease, and progression-free survival were similar between the two groups (Table 3). Moreover, the rate of side effects (leukopenia, thrombocytopenia, xerostomia, and restrictive pulmonary disease) after RAI were also similar between the two groups (Table 4). In patients with metastatic DTC, those who were pre-treated with THW achieved similar benefits from RAI therapy as those who were pre-treated with rhTSH.³¹

Table 3: Relative efficacy of rhTSH vs. THW with T3 preparation for RAI therapy ³¹

Parameter	Outcome		
	HR	95% CI	p-value
Complete response	0.97	0.08–11.42	0.982
Stable disease	3.22	0.79–13.18	0.104
Progressive disease	0.26	0.52–1.26	0.094
Progression-free survival	0.41	0.14–1.23	0.112
rhTSH, recombinant human thyrotropin; THW, thyroid hormone withdrawal; RAI, Radioactive iodine ablation			

Table 4: Side effects associated in both the groups ³¹

Side-effects	THW (%)	rhTSH (%)	p-value
Leukopenia	28	30	0.61
Thrombocytopenia	0	10	0.37
Xerostomia	12	0	0.20
Restrictive pulmonary disease	2	0	0.73
rhTSH, recombinant human thyrotropin; THW, thyroid hormone withdrawal			

A similar result was obtained from another meta-analysis of randomized controlled trials, where six trials with a total of 1,660 patients were included in a study to evaluate the effectiveness of THW vs. rhTSH prior RAI in thyroid cancer. The standard protocol for THW includes stopping LT4 therapy and switching to LT3 therapy for 2-4 weeks followed by withdrawal of LT3 for 2 weeks, or discontinuing LT4 therapy for 2-3 weeks without using LT3. Ablation success was defined as a thyroglobulin (Tg) cutoff of 1 ng/mL (risk ratio, 0.99; 95% confidence interval, 0.96-1.03) or a Tg cutoff of 1 ng/mL plus imaging modality (RR 0.97; 0.90-1.05). The results of the research revealed that there were no significant differences when ablation success was defined as a Tg cutoff of 2 ng/mL (RR 1.03; 0.95-1.11) or a Tg cutoff of 2 ng/mL plus imaging modality (RR 1.02; 0.95-1.09).³²

Various guidelines throw light on LT4 withdrawal and the use of LT3 as a part of a patient preparative method for RAI

Guideline	Recommendation/Consensus statement
2023 Patient preparation and radiation protection guidance for adult patients undergoing radioiodine treatment for thyroid cancer in the UK ³³	The traditional approach is withdrawal of thyroid hormone replacement (levothyroxine for 3–4 weeks or liothyronine for 2 weeks) combined with restricting iodine intake for up to 3 weeks prior to treatment.
2023 European Association of Nuclear Medicine (EANM) guideline on radioiodine therapy of benign thyroid disease ³⁴	Withdraw T3 medication 10–14 days before initiating RAI.
2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? ³⁵	For thyroid hormone withdrawal, one approach was switching from LT4 to LT3 for 2–3 weeks, followed by discontinuing LT3 for 2 weeks.
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer ³⁶	The experts strongly recommended to withdraw thyroid hormone 2-3 weeks prior to RAI. LT3 may be substituted for LT4 in the initial weeks if LT4 is withdrawn for 4 or more weeks. In such cases, LT3 should be withdrawn for at least 2 weeks. It is recommended to measure serum TSH prior to radioisotope administration to evaluate the degree of TSH elevation.
2015 The American Cancer Society ³⁷	To maximize the effectiveness of RAI therapy, the society advises patients to stop taking their thyroid hormone medication for several weeks prior to the treatment.

2009 American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer ³⁸	In patients undergoing RAI, endogenous TSH elevation can be achieved by switching to LT3 for 2–4 weeks followed by withdrawal of LT3 for 2 weeks.
---	---

Consensus statement


The standard protocol for THW includes stopping LT4 therapy and switching to LT3 therapy for 2–4 weeks followed by withdrawal of LT3 for 2 weeks. (A/I)

T3 medication should be withdrawn at least 10 days before initiating RAI. (A/I)

2. Clinical question: Which subset of hypothyroid patients would potentially benefit from LT3 therapy?

While T4 remains the preferred therapy for individuals with hypothyroidism, experts have also provided practical insights on the effective use of T3 in managing the condition. Patients who might benefit from LT3 therapy include those who report low satisfaction with LT4 treatment and continue to experience persistent symptoms, such as fatigue, despite having an optimized LT4 dosage. Additionally, LT3 can be administered to patients experiencing severe or symptomatic hypothyroidism requiring rapid symptom relief. This group may also include individuals awaiting pre-anesthetic clearance for surgery and those experiencing thyroid distress. Another set of individuals who may benefit from LT3 therapy are those with central or secondary hypothyroidism resulting from pituitary disease. The potential indicators for LT3 therapy are mentioned in Figure 1.²

Figure 1: Potential indicators for LT3 therapy²



3. Clinical question: What is the appropriate dose of LT3 when administered with LT4?

LT3 is prescribed as part of a combination therapy with LT4 for thyroid replacement. It can be used for both initiating treatment and for intensifying the therapy. LT3 can be administered at the same time as LT4, which is generally taken once daily before

breakfast. When prescribing this combination, the appropriate LT4:LT3 ratio must be determined. Additionally, when introducing LT3 into an existing LT4 regimen, deciding whether to maintain or reduce the current LT4 dosage is important.²

The LT4 /LT3 combination is used to initiate treatment in patients with severe symptoms or those seeking rapid relief from the disease. More commonly, LT3 is introduced for substitution (interchange) or intensification purposes. Substitution is required for patients who have reached biochemical euthyroidism but still display clinical signs of the disease. Intensification is recommended for individuals who still exhibit biochemical hypothyroidism (high TSH with or without low T3) despite receiving a sufficient dose of T4 (1.5–2 µg/kg/day) over an adequate duration (6–12 weeks). Dosage titration can be performed every 6 to 12 weeks, depending on the reason for initiating LT3 therapy.²

A randomized placebo-controlled trial was conducted by Brigante G, et al. (2024) on levothyroxine and liothyronine combination therapy in 160 patients with hypothyroidism after thyroidectomy. Medications were adjusted to keep the LT4/LT3 ratio between 13:1 and 20:1 and TSH was measured at all time points. This study showed no significant difference between those treated with LT4 alone or LT4+LT3 regarding peripheral tissue markers of thyroid function, quality of life, and BMI. The FT3/FT4 ratio persisted in the low range in the LT4+placebo group at the end of treatment, while the ratio increased to the normal range in the LT4+LT3 group.⁴³

Guideline	Recommendation/ consensus statement
Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement 2023 ¹⁴	- To initiate combination treatment, the panel recommended substituting LT3 at approximately 1/17th of the current LT4 dose; and reducing LT4 dose by three times the LT3 dose. - E.g. If the baseline LT4 dose is 100 µg, the LT3 dose is calculated to be approximately 1/17th of the current LT4 dose which is ~5 µg. The revised LT4 dose would therefore be ~ 85 µg (reduced by 3 times the LT3 dose)
Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A 2021 Consensus Document ³⁹	The panel recommended the pharmacological equivalence of LT3 to LT4 is approximately a 1:3
2015 American Thyroid Association Guideline on Treatment of Hospitalized Patients with Hypothyroidism and Use of Thyroid Hormone Analogs ⁴⁰	- In the management of myxedema coma, addition to LT4 therapy, LT3 therapy can be initiated at a dose of 5 to 20 µg, followed by a maintenance dose of 2.5 to 10 µg every 8 hours. - Lower doses of LT3 should be administered to patients who are smaller in stature, older, or have a history of coronary disease or arrhythmia.
2012 ETA guidelines: The use of LT4/LT3 in the treatment of hypothyroidism ¹¹	- Initiating the LT4/LT3 combination treatment with a dose ratio of 13:1 to 20:1 by weight. - Dividing the daily LT3 dose into two doses if possible,

	with one taken before breakfast and the larger dose before bedtime. Using separate LT4 and LT3 tablets for combination therapy as the currently available preparations contain an LT4/LT3 dose ratio lower than 13:1.
--	--

Consensus statement

LT3 can be administered at the same time as LT4, either as once daily or in divided doses to achieve ratio between 13:1 to 20:1. (B/IIa)

4. Clinical question: Does LT3 therapy require routine monitoring?

The necessity of continuing LT3 intake should be reassessed if a finite endpoint such as euthyroidism (to facilitate elective surgery) is achieved. The same evaluation should be made if symptoms persist, or surrogate laboratory results remain abnormal. In these situations, a thorough clinical evaluation should be conducted to identify the underlying cause of the concern for refractory hypothyroidism. Individuals who respond well to LT3 therapy may continue their treatment indefinitely, provided they are monitored with the same pharmacological and clinical vigilance as those undergoing T4 management.²

A 17-year population-based observational study was conducted to evaluate the adverse outcomes for patients on long-term LT3 therapy (n=400) compared to patients on LT4 therapy (n=33955). The results of the study revealed that patients on LT4 alone had a higher median TSH level (2.08 vs. 1.07 mU/L; p<0.001). The long-term treatment with LT3 was not associated with any additional risk of atrial fibrillation, cardiovascular disease, or fractures. There was an increase in antipsychotic use with T3 in this study. Hence monitoring the response to the treatment is important.⁴¹

Various guidelines have released the consensus statements for monitoring LT3 therapy in patients with hypothyroidism.

Guideline	Recommendation/ consensus statement
Evidence-Based Use of Levothyroxine/ Liothyronine Combinations in Treating Hypothyroidism: A 2021 Consensus Document ³⁹	- Administering LT3 once daily as part of an LT4/LT3 combination therapy results in increase of serum T3 level by up to 40% above baseline levels thus requiring adequate monitoring. - The panel agreed that monitoring serum T3 levels and free T3/free T4 ratios with conventional LT3 preparations is challenging due to 24-hour fluctuations. Consequently, interpreting TSH levels in patients on conventional LT3 preparations can also be difficult.
2012 ETA guidelines: The use of LT4/LT3 in the treatment of hypothyroidism ¹¹	The panel advised that LT4/LT3 combination therapy should be monitored with thyroid function tests on blood samples taken before the morning dose, with the aim to achieve normal levels of serum TSH, free T4, free T3, and

	the free T4/free T3 ratio. ● If adjustments to the LT4/LT3 combination therapy are needed to normalize serum TSH, free T4, free T3, and the free T4/free T3 ratio, it is recommended to alter the dose of only one component, preferably LT3.
--	--

Consensus statement

Routine monitoring of LT3 therapy is necessary with thyroid function tests including serum TSH, free T4, free T3, and the free T4/free T3 ratio. (C/IIa)

5. Clinical question: What are the contraindications associated with LT3 therapy?

A recent literature review elucidated that LT3 should not be used by women who are planning to conceive, those who are pregnant, or those who are breastfeeding. It is also advisable to avoid LT3 in patients with unstable heart disease or severe osteoporosis. Prescribers should be aware of the potential for LT3 misuse as a weight-loss drug.²

Various guidelines have delineated the contraindications associated with LT3 therapy.

Guideline	Recommendation/ consensus statement
2023 Joint British Thyroid Association/Society for endocrinology consensus statement on these of liothyronine (T3) in hypothyroidism ¹²	● The panel advised that LT3 should only be used as monotherapy in cases of confirmed allergy or intolerance to LT4 or its excipients. ● The experts unanimously recommended that LT3 should not be used in pregnancy.
2012 Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association ⁴²	The experts opined that thyroid hormones should not be used: ● To address symptoms indicative of hypothyroidism in the absence of biochemical confirmation of the diagnosis ● To treat obesity in euthyroid patients. ● In pregnant women or those planning pregnancy
2012 ETA Guidelines on the use of LT4/LT3 in the treatment of hypothyroidism ¹¹	● Combination therapy of LT3 and LT4 is not recommended for pregnant women or patients with cardiac arrhythmias.

Consensus statement

LT3 therapy is contraindicated in patients:

- Pregnant or planning pregnancy (C/I)
- Patients with cardiac arrhythmias (C/I)

Executive summary of the consensus statements

- There is limited evidence from randomized controlled trials and long-term studies demonstrating that the combination therapy is superior to LT4 alone, however majority of the patients have preferred the LT4/LT3 combination therapy. Hence, a trial of combined LT3 and LT4 therapy may be considered in patients on long-term levothyroxine therapy with ongoing symptoms and where other comorbidities have been ruled out. (A/IIb)
- No data is available regarding the optimal dose of LT4 and LT3 to be used in this situation in the perioperative period in People who require emergency surgery with sub optimally controlled hypothyroid status. If initiating thyroid replacement therapy for the first time, It may be prudent to initiate thyroid hormone therapy with low doses of LT3 (5-10 mcg every 8 hours IV or PO). If the patient is already on chronic therapy, 50% of prior dose may be continued as T4 and 50% as T3. (C/IIb)
- Administration of LT3 in addition to LT4 therapy in patients diagnosed with myxedema coma resulted in normalization of thyroid hormone levels and resolution of symptoms, leading to successful management of the disease. (D/IIa)
- Administration of LT3 therapy in patients diagnosed with myxedema coma was associated with lower mortality rates. However, a dose of ≥ 75 $\mu\text{g/day}$ was associated with fatal outcomes. (D/IIa)
- The standard protocol for THW includes stopping LT4 therapy and switching to LT3 therapy for 2-4 weeks followed by withdrawal of LT3 for 2 weeks. (A/I)
- LT3 medication should be withdrawn at least 10 days before initiating RAI. (A/I)
- LT3 can be administered at the same time as LT4, either as once daily or in divided doses to achieve ratio between 13:1 to 20:1. (B/IIa)
- Routine monitoring of LT3 therapy is necessary with thyroid function tests including serum TSH, free T4, free T3, and the free T4/free T3 ratio. (C/IIa)
- LT3 therapy is contraindicated in patients:
 - Pregnant or planning pregnancy (C/I)
 - Patients with cardiac arrhythmias (C/I)

References:

1. Chiovato L, Magri F, Carlé A. Hypothyroidism in context: Where we've been and where we're going. *Adv Ther.* 2019;36(Suppl 2):47–58.
2. Kalra S, Dhingra A, Kapoor N, et al. Practical and pragmatic usage of T3 in hypothyroidism. *Indian J Endocrinol Metab.* 2023;27(1):25–27.
3. Bajaj S. Thyrovigilance for hypothyroidism in India. *Thyroid Res and Pract.* 2022;19(1):1–7.
4. Unnikrishnan A, Kalra S, Sahay R, et al. Prevalence of hypothyroidism in adults: An epidemiological study in eight cities of India. *Indian J Endocrinol Metab.* 2013;17(4):647–52.
5. Van Tassell B, Wohlford G 4th, Linderman J, et al. Pharmacokinetics of L-triiodothyronine in patients undergoing thyroid hormone therapy withdrawal. *Thyroid.* 2019;29(10):1371–79.
6. Afsana. Treatment refractory hypothyroidism requiring high dose thyroxin replacement. *Glob J Otolaryngol.* 2021;23(5): 556124.

7. Hanmayyagari B. The etiology and treatment of refractory hypothyroidism-management issues: A cross sectional observational study. *IAR J of Med and Surgery Res.* 2020 Aug 10;1(1):36–8.
8. Benvenga S, Papi G, Antonelli A. Refractory hypothyroidism due to improper storage of levothyroxine tablets. *Front Endocrinol (Lausanne).* 2017;8:155.
9. Taylor P, Iqbal A, Minassian C, et al. Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. *JAMA Intern Med.* 2014 Jan;174(1):32–9.
10. Centanni M, Benvenga S, Sachmechi I. Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report. *J Endocrinol Invest.* 2017;40(12):1289–301.
11. Wiersinga W, Duntas L, Fadeyev V, et al. 2012 ETA Guidelines: The use of LT4+ L-T3 in the treatment of hypothyroidism. *Eur Thyroid J.* 2012;1(2):55–71.
12. Lan, Huiyu et al. “Combined T4 + T3 therapy versus T4 monotherapy effect on psychological health in hypothyroidism: A systematic review and meta-analysis.” *Clinical endocrinology* vol. 97,1 (2022): 13-25.
13. Akirov, A., Fazelzad, R., Ezzat, S., Thabane, L., & Sawka, A. M. (2019). A Systematic Review and Meta-Analysis of Patient Preferences for Combination Thyroid Hormone Treatment for Hypothyroidism. *Frontiers in endocrinology*, 10, 477.
14. Ahluwalia R, Baldeweg S, Boelaert K, et al. Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement. *Clin Endocrinol (Oxf).* 2023;99(2):206–16.
15. Jonklaas J, Bianco A, Bauer A, et al. Guidelines for the treatment of hypothyroidism: Prepared by the American thyroid association task force on thyroid hormone replacement. *Thyroid.* 2014;24(12):1670–51.
16. Brenta G, Vaisman M, Sgarbi J, et al. Clinical practice guidelines for the management of hypothyroidism. *Arquivos Brasileiros de Endocrinologia & Metabologia.* 2013;57:265–91.
17. Venkatesan T, Thomas N, Ponniah M, et al. Oral triiodothyronine in the perioperative management of central hypothyroidism. *Singapore Med J.* 2007;48(6):555–58.
18. Bennett-Guerrero E, Kramer D, Schwinn D. Effect of chronic and acute thyroid hormone reduction on perioperative outcome. *Anesth Analg.* 1997;85(1):30–6.
19. Gualandro D, Pinho C, Feitosa G, et al. I Guidelines for perioperative evaluation. *Arq Bras Cardiol.* 2007;89(6):210–37.
20. Palace M. Perioperative management of thyroid dysfunction. *Health Serv Insights.* 2017;10:1178632916689677.
21. Manzullo E, Ross D. Nonthyroid surgery in the patient with thyroid disease. *Lit Review Curr Through.* 2021.
22. Malhotra B, Bhadada S. Perioperative management for non-thyroidal surgery in thyroid dysfunction. *Indian J Endocrinol Metab.* 2022;26(5):428–34.
23. Elshimy G, Chippa V, Correa R. Myxedema. 2023. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 31424777.
24. Talha A, Houssam B, Brahim H. Myxedema coma: A review. *Eur J of Med and Health Sci.* 2020 Jun 26;2(3).
25. Ueda K, Kiyota A, Tsuchida M, et al. Successful treatment of myxedema coma with a combination of levothyroxine and liothyronine. *Endocr J.* 2019;66(5):469–74.
26. Werner S, Ingbar S, Braverman L, et al. *Werner & Ingbar's the thyroid: A fundamental and clinical text.* Lippincott Williams & Wilkins; 2005.
27. Ono Y, Ono S, Yasunaga H, et al. Clinical characteristics and outcomes of myxedema coma: Analysis of a national inpatient database in Japan. *J Epidemiol.* 2017;27(3):117–22.
28. Yamamoto T, Fukuyama J, Fujiyoshi A. Factors associated with mortality of myxedema coma: Report of eight cases and literature survey. *Thyroid.* 1999;9(12):1167–74.

29. Elghawy O, Hafey A, McCartney C, et al. Successful treatment of myxedema coma using levothyroxine and liothyronine in the setting of adrenal crisis and severe cardiogenic shock in a patient with apparent primary empty sella. *J of Clin and Trans Endocrinolo: Case Reports*. 2021;22:100095.
30. Tuttle R, Brokhin M, Omry G, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. *J Nucl Med*. 2008;49(5):764–70.
31. Klubo-Gwiedzinska J, Burman K, Van Nostrand D, et al. Radioiodine treatment of metastatic thyroid cancer: Relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. *Thyroid*. 2012;22(3):310–17.
32. Pak K, Cheon G, Kang K, et al. The effectiveness of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer: a meta-analysis of randomized controlled trials. *J Korean Med Sci*. 2014;29(6):811–17.
33. Wadsley J, Armstrong N, Bassett-Smith V, et al. Patient preparation and radiation protection guidance for adult patients undergoing radioiodine treatment for thyroid cancer in the UK. *Clin Oncol (R Coll Radiol)*. 2023;35(1):42–56.
34. Campennì A, Avram A, Verburg F, et al. The EANM guideline on radioiodine therapy of benign thyroid disease. *Eur J Nucl Med Mol Imaging*. 2023;50(11):3324–48.
35. Pacini F, Fuhrer D, Elisei R, et al. 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? *Eur Thyroid J*. 2022;11(1):e210046.
36. Haugen B, Alexander E, Bible K, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid*. 2016 (1):1–133.
37. American Cancer Society. Radioactive Iodine (Radioiodine) Therapy for Thyroid Cancer [Internet]. Available at: <https://www.cancer.org/cancer/types/thyroid-cancer/treating/radioactive-iodine.html>. Accessed on Jul 28, 2024.
38. Cooper D, Doherty G, Haugen B, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid*. 2009;19:1167–214.
39. Jonklaas J, Bianco A, Cappola A, et al. Evidence-based use of levothyroxine/liothyronine combinations in treating hypothyroidism: A consensus document. *Eur Thyroid J*. 2021;10(1):10–38.
40. Velanki. American Thyroid Association Guideline: Treatment of Hospitalized Patients with Hypothyroidism and Use of Thyroid Hormone Analogs. Available at: American Thyroid Association Guideline: Treatment of Hospitalized Patients with Hypothyroidism and Use of Thyroid Hormone Analogs (medcentral.com). Accessed on Jul 28, 2024.
41. Leese G, Soto-Pedre E, Donnelly L. Liothyronine use in a 17 year observational population-based study - the tears study. *Clin Endocrinol (Oxf)*. 2016;85(6):918–25.
42. Garber J, Cobin R, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. *Thyroid*. 2012;22(12):1200–35.
43. Brigante G, et al. Randomized double-blind placebo-controlled trial on levothyroxine and liothyronine combination therapy in totally thyroidectomized subjects: the LEVOLIO study. *Eur J Endocrinol* 2024;190(1):12-22